Computational Drug Design

Leveraging advanced algorithms and simulations to accelerate the discovery of novel therapeutics.

Revolutionizing Therapeutics Through Computation

Our computational drug design group is at the forefront of a paradigm shift in pharmaceutical research. By integrating sophisticated modeling, machine learning, and data analytics, we aim to identify, optimize, and validate drug candidates with unprecedented speed and accuracy.

🔬

Molecular Modeling & Simulation

Precise simulation of molecular interactions to understand binding affinities, predict efficacy, and explore complex biological systems.

Learn More
🤖

AI-Driven Drug Discovery

Utilizing machine learning for target identification, lead optimization, and predicting drug properties, dramatically reducing experimental costs.

Discover AI
📊

Virtual Screening

High-throughput virtual screening of vast chemical libraries to identify potential drug candidates that bind to specific disease targets.

Explore Screening
🧬

Structure-Based Design

Designing novel molecules based on the 3D structure of target proteins, ensuring optimal fit and interaction for maximum therapeutic effect.

View Design

Visualizing the Future of Medicine

Molecular simulation of drug binding

Simulating ligand-protein interactions for enhanced efficacy.

AI model predicting drug properties

AI model predicting pharmacokinetic properties of new drug candidates.

Our Advanced Methodologies

Molecular Dynamics

Simulating the movement and conformational changes of molecules over time to understand dynamic behavior and interactions.

Deep Learning for QSAR

Applying deep neural networks to quantitative structure-activity relationships, predicting biological activity from molecular structure.

Pharmacophore Modeling

Identifying key features of a molecule that are necessary for its biological activity, guiding the design of new compounds.

De Novo Design

Generating entirely new molecular structures computationally, optimized for specific targets and desired properties.